Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. News about ALZN often centers on the progress of its two main product candidates, AL001 and ALZN002, as well as financing transactions and corporate actions disclosed through press releases and SEC filings.
Investors following ALZN news can expect detailed updates on the company’s Phase II "Lithium in Brain" clinical program for AL001. These reports describe head-to-head studies of AL001 versus marketed lithium carbonate products, including enrollment milestones, dosing of the first patient, and completion of the clinical portion of trials in healthy subjects. Company announcements also highlight collaborations with Massachusetts General Hospital, Tesla Dynamic Coils BV and QMENTA to support high-resolution brain imaging and AI-driven analysis of lithium distribution.
Alzamend Neuro’s news flow also includes information on its ALZN002 active immunotherapy program targeting beta-amyloid in Alzheimer’s, operational developments in clinical trial management, and capital-raising activities such as private placements of preferred stock and related warrant issuances. Corporate updates, including reverse stock split decisions and governance matters reported on Form 8-K, are frequently summarized in press releases.
This ALZN news page aggregates these updates so readers can review clinical milestones, financing events and regulatory disclosures in one place. For those tracking the development of AL001 and ALZN002, or monitoring Alzamend Neuro’s Nasdaq-listed common stock, the news feed offers a consolidated view of the company’s publicly reported activities and announcements.
Ault Global Holdings (NYSE American: DPW) reported significant financial results for the nine months ending September 30, 2021. Revenue increased by 167% to $44.6 million, bolstered by lending and trading activities, contributing $19.6 million. However, Q3 saw a revenue decline of $36.5 million, totaling negative $30.8 million, mainly due to unrealized losses in investments, particularly a $33.4 million loss from Alzamend Neuro (Nasdaq: ALZN). Despite a net income of $1.3 million for nine months, Q3 net loss was $42.9 million.
Summary not available.
Alzamend Neuro has received FDA approval to proceed with a combined Phase 1 and 2 clinical trial for its Alzheimer’s treatment AL002. The therapy aims to utilize a mutant-peptide sensitized cell to enhance the immune system's ability to combat Alzheimer’s by reducing beta-amyloid plaques. Alzamend intends to file its IND application by the end of November 2021 and begin the clinical trial in early 2022, based on positive preclinical results and feedback from the FDA.
Alzamend Neuro has achieved a significant milestone by dosing the first group of participants in a six-month Phase I comparative study for AL001, aimed at treating dementia related to Alzheimer's disease. This study will assess the safety and pharmacokinetics of AL001 compared to conventional lithium treatments, involving at least 24 healthy participants. The company believes AL001 could offer significant improvements over existing therapies for the over 40 million Americans suffering from Alzheimer's.
Alzamend Neuro, Inc. (Nasdaq: ALZN) announced a partnership with Altasciences to conduct a six-month Phase I clinical study for AL001, aimed at treating dementia related to Alzheimer’s disease. The study, commencing in September 2021, will evaluate the pharmacokinetics of AL001 compared to a marketed lithium carbonate capsule. AL001 utilizes patented ionic cocrystal technology designed to enhance lithium delivery. Alzamend believes this formulation may significantly improve treatment options for Alzheimer’s and other neurodegenerative diseases, reducing potential regulatory burdens.
Alzamend Neuro, Inc. (Nasdaq: ALZN) announced an additional investment from Digital Power Lending, LLC, totaling $2 million for 1,333,333 shares at $1.50 each. This funding follows the FDA's approval for a Phase 1a study of AL001, a lithium-based therapy for Alzheimer's-related dementia. As part of a March 2021 agreement, further capital will be provided based on future milestones. CEO Stephan Jackman expressed gratitude for the support, indicating that the funding positions Alzamend well for advancing clinical trials without needing new capital.
Alzamend Neuro (Nasdaq: ALZN) has submitted a pre-IND meeting request to the FDA for AL002, a cell-based therapeutic vaccine aimed at combating Alzheimer’s by restoring the immune system's ability to fight the disease. Recent toxicology results have been positive, leading to plans for a Phase 1 clinical trial at Emory University School of Medicine to assess the treatment's safety and efficacy. This trial will enroll patients with early-stage Alzheimer’s for a year, including an interim statistical analysis after six months.
Alzamend Neuro (Nasdaq: ALZN) has received a favorable FDA study may proceed letter for its AL001 oral therapy aimed at treating dementia related to Alzheimer's disease. This Phase 1 trial is expected to commence in September 2021. AL001 utilizes a patented lithium-based ionic cocrystal technology, which has shown promising preclinical results, enhancing cognitive function and reducing behavioral issues in mice compared to traditional lithium treatments. The company’s pipeline also includes AL002, another innovative Alzheimer's treatment.
Alzamend Neuro, Inc. (Nasdaq: ALZN) announced positive results from a GLP toxicology study of its product AL002, aimed at treating Alzheimer’s disease. Conducted on a transgenic mouse model, the study showed no significant toxicity, with no treatment-related mortalities or adverse effects noted. CEO Stephan Jackman stated that these results are a critical milestone, as the company prepares to submit a Pre-Investigational New Drug Application for AL002 to the FDA. Alzamend aims to develop innovative treatments for neurodegenerative diseases at an affordable cost.
Alzamend Neuro (Nasdaq: ALZN) celebrates its recent Nasdaq listing by ringing the opening bell on July 12, 2021. The event is led by CEO Stephan Jackman and Chairman William B. Horne, marking a significant milestone for stockholders and the ongoing fight against Alzheimer’s disease. Alzamend has raised approximately $14.4 million through its IPO, which will fund operations and clinical trials. The company is advancing its therapeutic candidate, AL001, and aims to develop innovative treatments for Alzheimer's and other neurodegenerative diseases.
FAQ
What is the current stock price of Alzamend Neuro (ALZN)?
What is the market cap of Alzamend Neuro (ALZN)?
